Shares of Apogee Therapeutics Inc. (NASDAQ:APGE) soared 24% in Monday’s session following encouraging results from its Phase ...

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...

Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main ...

Apogee Therapeutics, Inc. (NASDAQ:APGE) is one of the 10 Stocks Crash Hard Alongside Wall Street. Apogee Therapeutics fell by ...

Amarna Therapeutics and NorthX Biologics finalized an agreement to advance Nimvec AM510 gene therapy toward clinical trials for Type 1 Diabetes. Now in its fourth year, the MM+M Media Summit brings ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

Shares of Apogee Therapeutics, Inc. APGE +46.5% + Free Alerts rose sharply in today's pre-market trading after the company ...

Shares of US clinical-stage biotech Apogee Therapeutics closed down 17.3% at $39.24 yesterday, despite announcing positive 16 ...

Apogee Therapeutics said Monday that its experimental antibody treatment alleviated the signs and symptoms of atopic dermatitis, a common inflammatory skin condition, far more than a placebo ...

Apogee's APG777 showed a 71% drop in eczema severity and strong itch relief in a Phase 2 trial for atopic dermatitis. Part B ...

Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best hot stocks to buy according to Wall Street analysts. Earlier in May ...